Gilead Sciences, Inc. (GILD): Operating Income
$10.02B
Year ended 2025-12-31
-$2.50B
Trailing 12 months to 2026-06-30
+11.0%
3-year compound annual growth
+19.7%
5-year compound annual growth
-7.6%
10-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.02B | +503.0% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $1.66B | -78.1% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $7.61B | +3.8% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $7.33B | -26.1% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $9.92B | +143.6% | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | $4.07B | -5.0% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $4.29B | -47.7% | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | $8.20B | -41.9% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $14.12B | -19.9% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $17.63B | -20.5% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $22.19B | +45.4% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $15.27B | +237.4% | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | $4.52B | +12.8% | 2016-02-24, From 2013-01-01 |
| 2012-12-31 | $4.01B | +5.8% | 2015-02-25, From 2012-01-01 |
| 2011-12-31 | $3.79B | -4.4% | 2014-02-25, From 2011-01-01 |
| 2010-12-31 | $3.96B | +12.3% | 2013-02-27, From 2010-01-01 |
| 2009-12-31 | $3.53B | +31.8% | 2012-02-23, From 2009-01-01 |
| 2008-12-31 | $2.68B | +23.7% | 2011-02-28, From 2008-01-01 |
| 2007-12-31 | $2.16B | n/a | 2010-03-01, From 2007-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $10.02B | +503.0% |
| Amgen Inc (AMGN) | 2025-12-31 | $9.08B | +25.1% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $619.10M | +8.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $872.19M | +44.3% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $465.85M | +376.8% |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$3.07B | n/m |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $469.01M | -15.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $251.89M | +146.3% |
| Novavax Inc (NVAX) | 2025-12-31 | $452.80M | n/m |
Compare GILD, AMGN, NBIX, EXEL side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗